๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Esophageal Squamous Cell Carcinoma Stage II

Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma NCT05937438Phase 1, Phase 21 site๐Ÿ“ Hefei Anhui Provincial Hospital ยท Tests: Immune Checkpoint Inhibitors A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ Columbus Tanabe Pharma America, Inc. ยท Tests: MT-4561 A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma NCT06843889Phase 21 site๐Ÿ“ Guangzhou Nanfang Hospital, Southern Medical University ยท Tests: Toripalimab (240mg day1, Q3W*3cycle) Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06988956Phase 21 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: Nimotuzumab, Tegafur, radiotherapy A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) NCT07863141Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: anlotinib + PD-1 inhibitor, PD-1 inhibitor Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers NCT04221893NA2 sites๐Ÿ“ San Francisco๐Ÿ“ Walnut Creek University of California, San Francisco ยท Tests: Radiation Therapy (RT) Becotatug Vedotin ยฑ Anti-PD-1 in Pretreated Advanced ESCC NCT07403136Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: Vebrekotuzumab, PD-1 antibody Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07559045Phase 21 site๐Ÿ“ Zunyi Second Affiliated Hospital of Zunyi Medical University ยท Tests: Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy), Weekly Paclitaxel plus Cisplatin or Carboplatin (Conโ€ฆ Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma NCT06912074Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Induction chemoimmunotherapy, Hypofractionated Radiation Therapy, Conventional Fractionated Radiation Therapy, Concurreโ€ฆ Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC NCT07038629Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: S1, Iparomlimab, Radiation Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors NCT06535607Phase 298 sites๐Ÿ“ Los Angeles๐Ÿ“ Baltimore๐Ÿ“ New York AstraZeneca ยท Tests: Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors NCT06747585Phase 1, Phase 241 sites๐Ÿ“ Scottsdale๐Ÿ“ Fullerton๐Ÿ“ Los Angeles Alentis Therapeutics AG ยท Tests: ALE.P02, Pembrolizumab Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma๏ผˆCRIS-2 Trial๏ผ‰ NCT06509568Phase 21 site๐Ÿ“ Hangzhou Zhejiang Cancer Hospital ยท Tests: Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma NCT07484724Phase 21 site๐Ÿ“ Beijing Shanghai Junshi Bioscience Co., Ltd. ยท Tests: JS212, JS001, 5-FU PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY NCT06354140Phase 21 site๐Ÿ“ Chongqing Daping Hospital and the Research Institute of Surgery of thโ€ฆ ยท Tests: Tegafur Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma NCT06329869Phase 21 site๐Ÿ“ Taipei National Taiwan University Hospital ยท Tests: Sacituzumab govitecan Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC NCT04973306Phase 2, Phase 31 site๐Ÿ“ Shanghai Shanghai Zhongshan Hospital ยท Tests: Neoadjuvant Chemoradiotherapy, Tislelizumab, Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended) SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma NCT07700667Phase 224 sites๐Ÿ“ Changchun๐Ÿ“ Chengdu๐Ÿ“ Chengdu Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB500, Tislelizumab, Cisplatin, 5 - FU A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) NCT06709417Phase 21 site๐Ÿ“ Shanghai Shanghai Chest Hospital ยท Tests: Sintilimab, Chemotherapy, radiotherapy Chemoradiotherapy in Unresectable Esophageal Cancer NCT04278287Phase 1, Phase 25 sites๐Ÿ“ Anyang๐Ÿ“ Changsha๐Ÿ“ Nanjing Cancer Institute and Hospital, Chinese Academy of Medical Sโ€ฆ ยท Tests: Radiotherapy, Albumin-Bound Paclitaxel, Cisplatin Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer NCT06430658Phase 21 site๐Ÿ“ Beijing Cancer Institute and Hospital, Chinese Academy of Medical Sโ€ฆ ยท Tests: Tislelizumab (BGB-A317) with chemoradiotherapy KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer NCT07481058Phase 21 site๐Ÿ“ Beijing Beijing Konruns Pharmaceutical Co., Ltd. ยท Tests: KC1036, Toripalimab, Paclitaxel, Cisplatin, KC1036 Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site๐Ÿ“ Jacksonville Mayo Clinic ยท Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma NCT06410651Phase 21 site๐Ÿ“ Beijing Cancer Institute and Hospital, Chinese Academy of Medical Sโ€ฆ ยท Tests: Nimotuzumab with chemoradiotherapy Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma NCT07152678Phase 21 site๐Ÿ“ Huwei National Taiwan University Hospital ยท Tests: Nivolumab (240 mg), Brachytherapy Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma NCT06675201Phase 21 site๐Ÿ“ Chengdu Sichuan University ยท Tests: neoantigen-loaded dendritic cell vaccine (NeoDC-Vac) Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma NCT07188103Phase 21 site๐Ÿ“ Hefei Anhui Provincial Hospital ยท Tests: Ivonescimab+Radiotherapy A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy NCT06769113Phase 21 site๐Ÿ“ Jinan Shanghai Henlius Biotech ยท Tests: HLX43 Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma NCT07039162Phase 28 sites๐Ÿ“ Kaohsiung City๐Ÿ“ Kaohsiung City๐Ÿ“ Taichung Ming-Yu Lien ยท Tests: Tislelizumab, Paclitaxel, Cisplatin, Radiation Therapy Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC NCT06601309Phase 21 site๐Ÿ“ Fuzhou Fujian Medical University Union Hospital ยท Tests: Serplulimab, Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy), Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy), Radioโ€ฆ
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy